Crescita Therapeutics

What Crescita Therapeutics does

Crescita Therapeutics is a Canadian commercial dermatology company headquartered in Laval, Quebec, that develops, manufactures, and distributes a diversified portfolio of prescription and non-prescription skincare, topical anesthetics, and in-clinic aesthetic products. The company sells through three primary customer segments: healthcare professionals (dermatologists, plastic surgeons, aesthetic physicians, and medical spas), direct-to-consumer channels (e-commerce via alyriaskincare.com and amazon.ca, plus Familiprix retail pharmacies in Quebec and New Brunswick), and B2B contract development and manufacturing organization (CDMO) clients served globally from its 50,000 sq. ft. Health Canada-approved facility.\n\nThe product portfolio spans five OTC skincare brands (Laboratoire Dr Renaud, Aquafolia, Pro-Derm, Obagi, and Alyria), three in-clinic products (NCTF Boost 135HA anti-aging complex, Art Filler hyaluronic acid-based fillers with lidocaine, and the MicronJet MEMS-based microneedle injection device), and one prescription product (Pliaglis, a lidocaine-tetracaine 7%/7% peel-off topical anesthetic licensed in 40 countries). Underlying technology includes two patented transdermal delivery platforms, over 250 proprietary stable formulations across creams, gels, serums, and other formats, and integrated R&D, regulatory, and quality capabilities supporting both proprietary and CDMO work. Exclusive Canadian distribution rights with Fillmed (NCTF Boost 135HA, Art Filler) and NanoPass (MicronJet) anchor the in-clinic product line.\n\nThe business model combines branded product sales (one-time product revenue across OTC, in-clinic, and prescription channels), contract manufacturing fees (professional services revenue from private-label and custom development for third-party skincare brands), and historical licensing royalties (Pliaglis international rights, partially retained after the May 2025 termination of the Croma Pharma agreement). The company was publicly traded on the TSX under CTX:CA from inception until its June 2026 acquisition by ClinActiv Holdings Inc. for approximately $14.9 million. Reported FY2025 revenue was CAD 21.118 million, and Q1 2026 revenue was CAD $5,637K, up 59% year-over-year driven by the Occy acquisition and incremental skincare volumes.

Name

Crescita Therapeutics

Legal name

Crescita Skin Science

Website

https://crescitatherapeutics.com

Company type

Public

Founded year

2016

Operating status

Acquired

Headcount range

51–100 employees

Short description

Crescita Therapeutics is a Canadian commercial dermatology company that develops, manufactures, and distributes prescription and OTC skincare, in-clinic aesthetic devices, and topical anesthetics, and operates a CDMO business from its Health Canada-approved Laval, Quebec facility. The company was acquired by ClinActiv Holdings in June 2026.

Ownership category

akta.pro rank

Product category

Dermatology Pharmaceuticals and Skincare

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medical Equipment and Supplies Manufacturing (3391), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Perfumes, Cosmetics & Other Toilet Preparations (2844), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Dermocosmetics & Medical-Grade Skincare (CRABAAAF)

Keywords

• Commercial dermatology products
• Prescription skincare brands
• Topical anesthetic cream
• Dermatology contract manufacturing
• Aesthetic medicine products

Headquarters

HQ city

Mississauga

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. Product Sales: Crescita generates revenue through the sale of its portfolio of prescription and non-prescription skincare products including Laboratoire Dr Renaud, Aquafolia, Pro-Derm, Obagi, Alyria, NCTF Boost 135HA, Art Filler, MicronJet, and Pliaglis through multiple distribution channels.
2. Contract Manufacturing Services (CDMO): Crescita provides contract manufacturing and contract development services to clients worldwide from its 50,000 sq. ft. Health Canada-approved facility. Services include integrated R&D, supply chain management, regulatory and quality functions, offering both ready-to-go private label solutions and customized product development.
3. Licensing Royalties: Crescita previously generated licensing revenue through agreements for Pliaglis in international territories. The company regained development and commercialization rights for Pliaglis in 9 territories following the mutual termination of the Croma Pharma licensing agreement in 2025.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

Crescita Therapeutics is a Canadian commercial dermatology company that develops, manufactures, and distributes a portfolio of prescription and non-prescription skincare products and in-clinic aesthetic products under brands including Laboratoire Dr Renaud, Aquafolia, Pro-Derm, Obagi, Alyria, NCTF Boost 135HA, Art Filler, MicronJet, and Pliaglis. The company also operates as a contract development and manufacturing organization (CDMO) from a 50,000 sq. ft. Health Canada-approved facility in Laval, Quebec, offering integrated R&D, supply chain, regulatory, and quality services, including private label and custom product development to third-party skincare and pharmaceutical clients worldwide.

Product overview

Crescita Therapeutics is a Canadian commercial dermatology company offering a diversified portfolio of non-prescription and prescription skincare products and dermatological solutions. The portfolio includes five over-the-counter skincare brands (Laboratoire Dr Renaud, Aquafolia, Pro-Derm, Obagi, Alyria) and three in-clinic products (NCTF Boost 135HA, Art Filler, MicronJet device). The company also markets one prescription product (Pliaglis, a topical anesthetic). Crescita operates as both a commercial entity with in-house R&D and manufacturing capabilities, and as a contract development and manufacturing organization (CDMO) offering private label and custom manufacturing services. Crescita was acquired by ClinActiv Holdings Inc. in June 2026.

Differentiator

Problem solved

Functional benefit

Brands

• Laboratoire Dr Renaud: Over-the-counter skincare brand founded over 70 years ago, a pioneer in the cosmetics industry and proud Canadian brand since 1963.
• Aquafolia
• Pro-Derm
• Obagi
• Alyria
• NCTF Boost 135HA
• Art Filler
• MicronJet
• Pliaglis

Products and services

• Pliaglis A prescription topical anesthetic cream (lidocaine 7% and tetracaine 7%) utilizing proprietary phase-changing peel-off technology to provide safe and effective local dermal analgesia on intact skin prior to superficial dermatological procedures; licensed in 40 countries.
• NCTF Boost 135HA A unique non-prescription in-clinic anti-aging complex containing non cross-linked HA (5mg/ml) and New Cellular Treatment Factor (NCTF) for topical application in clinics that smooths wrinkles, reduces signs of aging, and protects skin from environmental stressors.
• Art Filler An exclusive collection of hyaluronic acid-based fillers with lidocaine featuring Tri-Hyal technology, distributed exclusively in Canada to smooth superficial-to-deep wrinkles and restore facial volume and contours; includes FINE LINES, UNIVERSAL, and CONTOUR variants.
• MicronJet An advanced intradermal injection device using patented MEMS microneedle design with three silicon crystal delivery pyramids and 0.6mm needle size for virtually pain-free and precise aesthetic injections; holds FDA clearance and CE certification.
• Laboratoire Dr Renaud A non-prescription Canadian skincare brand founded over 70 years ago (proud Canadian since 1963) uniting dermatology with aesthetic care, featuring medical-grade ingredients such as retinol, vitamin C, hyaluronic acid, and peptides.
• Aquafolia A non-prescription skincare brand combining biotechnology with botanical extracts, incorporating gemmotherapy and probiotic technologies to create intelligent cosmeceutical anti-aging products.
• Pro-Derm A non-prescription dermaceutical product line developed in Montreal since 1996 based on clinical and scientific research, featuring optimized active ingredients for facial rejuvenation and natural vegetable-based formulations.
• Obagi A non-prescription skincare brand established in 1988 with over 30 years of clinical experience, designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage.
• Alyria A non-prescription medical-grade skincare line developed using over 20 years of scientific research targeting major skin concerns, using clinically proven active ingredients in optimal concentrations; sold through alyriaskincare.com, amazon.ca, and Familiprix pharmacies.
• Contract Manufacturing Services (CDMO) Full-service contract development and manufacturing from a 50,000 sq. ft. Health Canada-approved facility in Laval, Quebec, providing integrated R&D, supply chain management, quality assurance/control, and regulatory services; offers over 250 proprietary formulations and ready-to-go private label and customized product development for global B2B clients.

Quantifiable outcome

• Q1 2026 revenue increased 59% year-over-year to $5,637K
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered former (terminated), core and minor.

• Croma Pharma GmbHformer (terminated)OEM/ Whitelabel/ Licensing Partner · 23 May 2025Licensing agreement for Pliaglis in nine territories including Germany, UK, Ireland, Switzerland, Brazil, Romania, Belgium, Netherlands, and Luxembourg was mutually terminated in May 2025 following Croma's strategic portfolio rationalization. Crescita regained development and commercialization rights and received €575,000 from Croma.
• NanoPass TechnologiescoreChannel Partner/ Reseller/ Distributor · 19 August 2024Exclusive distribution agreement for MicronJet 600 intradermal injection device in Canada, pending Health Canada approval expected in first half of 2025. The device uses MEMS technology with three silicon crystal delivery pyramids for virtually pain-free aesthetic injections.
• FillmedcoreChannel Partner/ Reseller/ DistributorFillmed is the manufacturer of NCTF Boost 135HA and Art Filler product lines. Crescita serves as the exclusive Canadian distributor for these products, which are sold to healthcare professionals including dermatologists, plastic surgeons, and aesthetic physicians.
• ObagicoreChannel Partner/ Reseller/ DistributorObagi is a skincare brand founded in 1988 with over 30 years of clinical experience. Crescita distributes Obagi products in Canada through professional healthcare channels including dermatologists, plastic surgeons, and medical spas.
• NefelibataminorChannel Partner/ Reseller/ DistributorNefelibata skincare brand partnered with Crescita for distribution in Canada.
• Keren BartovminorChannel Partner/ Reseller/ DistributorKeren Bartov skincare brand partnered with Crescita for distribution in Canada.
• Sans FaconminorChannel Partner/ Reseller/ DistributorSans Facon cosmetics brand partnered with Crescita for distribution in Canada.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Taro Pharmaceutical Industries: Generic and specialty pharmaceutical manufacturer with a significant dermatology franchise. Comparable as a broader dermatology and topical-product incumbent with overlapping contract manufacturing capabilities.
• Bausch Health: Large diversified specialty pharma with a substantial dermatology franchise (Bausch + Lomb, Ortho Dermatologics). Comparable as a broad incumbent that overlaps with Crescita in dermatology and aesthetics but operates at vastly greater scale across many therapeutic categories.

Direct peers

• Galderma: Pure-play global dermatology company offering prescription, OTC, and aesthetic skincare products. Highly comparable as both companies compete in dermatology with prescription (Pliaglis vs. Galderma's therapeutics) and aesthetic (NCTF Boost 135HA vs. Galderma fillers) product lines.
• DPT Laboratories (DPT Center of Excellence): CDMO specializing in semi-solids, liquids, and topical pharmaceutical manufacturing. Highly comparable to Crescita's CDMO business segment given similar formulation and topical-product manufacturing capabilities.

Regional players

• Cipher Pharmaceuticals: Canadian specialty pharmaceutical company commercializing prescription skincare and dermatology products. Comparable as a Canada-based dermatology and specialty pharma peer with overlapping distribution channels to physicians and pharmacists.
• Knight Therapeutics: Canadian specialty pharmaceutical company that was Crescita's largest shareholder (10.4%) prior to the ClinActiv acquisition. Highly comparable as a Canadian-headquartered specialty pharma focused on in-licensing and commercializing innovative products.

Emerging players

• MedPharm: CDMO specializing in topical and transdermal pharmaceutical development and manufacturing. Comparable as a peer offering contract development services for dermatology and topical products, with overlapping formulation expertise.
• Arcutis Biotherapeutics: Dermatology-focused biopharma developing topical treatments for inflammatory skin conditions. Comparable as a specialty dermatology player targeting similar physician channels, though focused more on prescription therapeutics than consumer skincare.
• Dermavant Sciences: Dermatology-focused biopharma developing novel topical therapies. Comparable as a dermatology-specialized emerging player with similar physician-channel focus, though concentrated in prescription therapeutics rather than OTC or aesthetics.
• Sol-Gel Technologies: Dermatology company developing topical branded generics and innovative therapies. Comparable as a focused dermatology player with overlapping prescription product categories targeting similar physician customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/crescita-therapeutics-inc.

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Crescita Therapeutics